Evaluating Efficacy of Antiseptic Mouth Rinses on Salivary SARS-CoV-2 Infectivity
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 5R03DE031301-02
Grant search
Key facts
Disease
COVID-19Start & end year
20222025Known Financial Commitments (USD)
$155,500Funder
National Institutes of Health (NIH)Principal Investigator
ASSISTANT PROFESSOR Laura JacoxResearch Location
United States of AmericaLead Research Institution
UNIV OF NORTH CAROLINA CHAPEL HILLResearch Priority Alignment
N/A
Research Category
Infection prevention and control
Research Subcategory
Barriers, PPE, environmental, animal and vector control measures
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
ABSTRACT Evaluating the antiviral potential of widely available commercial antiseptic rinses on SARS-CoV-2 infectivity holds great potential for rapidly reducing viral transmission, particularly as novel strains emerge. Given that SARS- CoV-2 is transmitted primarily through aerosols and salivary and respiratory secretions, strategies to reduce viral burden is an attractive approach to mitigating spread; this is particularly true for dental and other healthcare settings which have high patient volumes, require work in close proximity to the head and neck, and generate procedural aerosols. Though studies have demonstrated that some antiseptic mouth rinses have antiviral properties against SARS-CoV-2 in vitro and other enveloped viruses in vivo, data are still emerging from recent randomized clinical trials (RCT), including ours at the Adams School of Dentistry, regarding whether antiseptic mouth rinses reduce SARS-CoV-2 in vivo. To address this gap in knowledge, we propose to determine whether mouth rinses containing ethanol, hydrogen peroxide, povidone-iodine, chlorhexidine, or cetylpyridinium chloride reduce SARS-CoV-2 viral load, replication and infectivity (Aim 1) and to characterize salivary inflammatory and antibody responses associated with early SARS-CoV-2 infection (Aim 2) using salivary samples derived from our recent COVID-19+ patient RCT. Altogether, the data generated from these aims will demonstrate whether antiseptic rinses reduce salivary SARS-CoV-2 viral load and infectivity, and will characterize the local inflammatory response to SARS-CoV-2 in the oral cavity with the ultimate goal of limiting viral spread. These studies will generate data to develop feasible, inexpensive, rapidly implementable protocols to mitigate the spread of SARS-CoV-2 and address this urgent public health need with broad translational impact. Our interdisciplinary team is uniquely qualified to conduct the proposed work as we have the innovative methodologies, BLS2+ facilities, SARS-CoV-2+ samples, and expertise to achieve our aims. This application includes collaboration between experienced and junior faculty across multiple disciplines to ensure the rigor and translatability of our findings.